Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease

Open access

Abstract

Cerebrospinal fluid (CSF) amyloid-β peptide (Aβ)42/Aβ40 and the concentration of tau phosphorylated at site 181 (p-tau181) are well-established biomarkers of Alzheimer’s disease (AD). The present study used mass spectrometry to measure concentrations of nine phosphorylated and five nonphosphorylated tau species and phosphorylation occupancies (percentage phosphorylated/nonphosphorylated) at ten sites. In the present study we show that, in 750 individuals with a median age of 71.2 years, CSF pT217/T217 predicted the presence of brain amyloid by positron emission tomography (PET) slightly better than Aβ42/Aβ40 ( P = 0.02). Furthermore, for individuals with positive brain amyloid by PET ( n = 263), CSF pT217/T217 was more strongly correlated with the amount of amyloid (Spearman’s ρ = 0.69) than Aβ42/Aβ40 ( ρ = −0.42, P < 0.0001). In two independent cohorts of participants with symptoms of AD dementia ( n = 55 and n = 90), CSF pT217/T217 and pT205/T205 were better correlated with tau PET measures than CSF p-tau181 concentration. These findings suggest that CSF pT217/T217 and pT205/T205 represent improved CSF biomarkers of amyloid and tau pathology in AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43587-023-00380-7

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Correlations of CSF measures with amyloid PET Centiloid, the tau PET summary measure or dementia severity. a, Correlations of the CSF measures with amyloid PET Centiloid evaluated in the amyloid PET cohort (n = 750 individuals). b, Correlations with the tau PET summary measure evaluated in the tau PET cohort (n = 371 individuals). c, Correlations with dementia severity, as measured by the CDR-SB, evaluated in the larger amyloid PET cohort (n = 750 individuals). The lines represent Spearman’s correlation (middle point) with 95% CIs. The black lines represent correlations in the entire cohort and the red lines represent correlations in amyloid PET-positive individuals.
Fig. 1 Correlations of CSF measures with amyloid PET Centiloid, the tau PET summary measure or dementia severity. a, Correlations of the CSF measures with amyloid PET Centiloid evaluated in the amyloid PET cohort (n = 750 individuals). b, Correlations with the tau PET summary measure evaluated in the tau PET cohort (n = 371 individuals). c, Correlations with dementia severity, as measured by the CDR-SB, evaluated in the larger amyloid PET cohort (n = 750 individuals). The lines represent Spearman’s correlation (middle point) with 95% CIs. The black lines represent correlations in the entire cohort and the red lines represent correlations in amyloid PET-positive individuals.CC BY · PubMed Central
Fig. 2 Correlations of selected CSF p-tau concentrations and tau phosphorylation occupancies with amyloid PET Centiloid. a–j, CSF concentrations of p-tau217 (a), p-tau231 (c), p-tau181 (e), p-tau205 (g) and Aβ42 (i), and tau phosphorylation occupancies at T217 (b), T231 (d), T181 (f) and T205 (h), as well as Aβ42/Aβ40 (j), plotted as a function of amyloid PET Centiloid. Spearman’s correlations with 95% CIs are shown for the entire amyloid PET cohort (n = 750 individuals) and amyloid PET-positive individuals in the amyloid PET cohort (n = 263). The horizontal dashed lines denote the cut-offs that best distinguish amyloid PET status, based on combined sensitivity and specificity (Supplementary Table 3). The vertical dashed lines represent the cut-off for amyloid PET positivity. Each symbol represents one individual: blue circle: amyloid PET negative, CSF negative, CDR = 0; blue square: amyloid PET negative, CSF negative, CDR > 0; green circle: amyloid PET negative, CSF positive, CDR = 0; green square: amyloid PET negative, CSF positive, CDR > 0; green triangle: amyloid PET positive, CSF negative, CDR = 0; orange circle: amyloid PET positive, CSF positive, CDR = 0; red circle: amyloid PET positive, CSF positive, CDR = 0.5; and red square: amyloid PET positive, CSF positive, CDR > 0.5.
Fig. 2 Correlations of selected CSF p-tau concentrations and tau phosphorylation occupancies with amyloid PET Centiloid. a–j, CSF concentrations of p-tau217 (a), p-tau231 (c), p-tau181 (e), p-tau205 (g) and Aβ42 (i), and tau phosphorylation occupancies at T217 (b), T231 (d), T181 (f) and T205 (h), as well as Aβ42/Aβ40 (j), plotted as a function of amyloid PET Centiloid. Spearman’s correlations with 95% CIs are shown for the entire amyloid PET cohort (n = 750 individuals) and amyloid PET-positive individuals in the amyloid PET cohort (n = 263). The horizontal dashed lines denote the cut-offs that best distinguish amyloid PET status, based on combined sensitivity and specificity (Supplementary Table 3). The vertical dashed lines represent the cut-off for amyloid PET positivity. Each symbol represents one individual: blue circle: amyloid PET negative, CSF negative, CDR = 0; blue square: amyloid PET negative, CSF negative, CDR > 0; green circle: amyloid PET negative, CSF positive, CDR = 0; green square: amyloid PET negative, CSF positive, CDR > 0; green triangle: amyloid PET positive, CSF negative, CDR = 0; orange circle: amyloid PET positive, CSF positive, CDR = 0; red circle: amyloid PET positive, CSF positive, CDR = 0.5; and red square: amyloid PET positive, CSF positive, CDR > 0.5.CC BY · PubMed Central
Fig. 3 Correlations of selected CSF p-tau concentrations and tau phosphorylation occupancies with the tau PET summary measure. a–j, CSF concentrations of p-tau205 (a), p-tau217 (c), p-tau208 (e), p-tau231 (g) and p-tau181 (i), and tau phosphorylation occupancies at T205 (b), T217 (d), S208 (f), T231 (h), and T181 (j), plotted as a function of the tau PET summary measure. Spearman’s correlations with 95% CIs are shown for the entire tau PET cohort (n = 371) and amyloid PET-positive individuals in the tau PET cohort (n = 125). The horizontal dashed lines denote the cut-offs that best distinguish tau PET status, based on combined sensitivity and specificity (Supplementary Table 9). The vertical dashed lines represent the cut-off for tau PET positivity. Each symbol represents one individual: blue circle: amyloid PET negative, CSF negative, CDR = 0; blue square: amyloid PET negative, CSF negative, CDR > 0; green circle: amyloid PET negative, CSF positive, CDR = 0; green square: amyloid PET negative, CSF positive, CDR > 0; green triangle: amyloid PET positive, CSF negative, CDR = 0; orange circle: amyloid PET positive, CSF positive, CDR = 0; red circle: amyloid PET positive, CSF positive, CDR = 0.5; and red square: amyloid PET positive, CSF positive, CDR > 0.5.
Fig. 3 Correlations of selected CSF p-tau concentrations and tau phosphorylation occupancies with the tau PET summary measure. a–j, CSF concentrations of p-tau205 (a), p-tau217 (c), p-tau208 (e), p-tau231 (g) and p-tau181 (i), and tau phosphorylation occupancies at T205 (b), T217 (d), S208 (f), T231 (h), and T181 (j), plotted as a function of the tau PET summary measure. Spearman’s correlations with 95% CIs are shown for the entire tau PET cohort (n = 371) and amyloid PET-positive individuals in the tau PET cohort (n = 125). The horizontal dashed lines denote the cut-offs that best distinguish tau PET status, based on combined sensitivity and specificity (Supplementary Table 9). The vertical dashed lines represent the cut-off for tau PET positivity. Each symbol represents one individual: blue circle: amyloid PET negative, CSF negative, CDR = 0; blue square: amyloid PET negative, CSF negative, CDR > 0; green circle: amyloid PET negative, CSF positive, CDR = 0; green square: amyloid PET negative, CSF positive, CDR > 0; green triangle: amyloid PET positive, CSF negative, CDR = 0; orange circle: amyloid PET positive, CSF positive, CDR = 0; red circle: amyloid PET positive, CSF positive, CDR = 0.5; and red square: amyloid PET positive, CSF positive, CDR > 0.5.CC BY · PubMed Central
Fig. 4 Correlations of selected CSF tau phosphorylation occupancies with regional tau PET and regional brain volumes for amyloid PET-positive individuals. a, Partial Spearman’s correlations of selected CSF measures with regional tau PET adjusted for age and sex shown for amyloid PET-positive individuals in the tau PET cohort (n = 125). b, Partial Spearman’s correlations of CSF measures with regional brain volumes adjusted for age and sex shown for amyloid PET-positive individuals in the larger amyloid PET cohort (n = 263).
Fig. 4 Correlations of selected CSF tau phosphorylation occupancies with regional tau PET and regional brain volumes for amyloid PET-positive individuals. a, Partial Spearman’s correlations of selected CSF measures with regional tau PET adjusted for age and sex shown for amyloid PET-positive individuals in the tau PET cohort (n = 125). b, Partial Spearman’s correlations of CSF measures with regional brain volumes adjusted for age and sex shown for amyloid PET-positive individuals in the larger amyloid PET cohort (n = 263).CC BY · PubMed Central
Extended Data Fig. 1 Correspondence of CSF measures with amyloid PET status, tau PET status, or clinical status. Correspondence of the CSF measures with amyloid PET status was evaluated in the amyloid PET cohort (n = 750 individuals) (A), and correspondence with tau PET status was evaluated in tau PET cohort (n = 371 individuals) (B). Correspondence of the CSF measures with clinical status (cognitively normal [CDR = 0] or cognitively impaired [CDR > 0]) was evaluated in the larger amyloid PET cohort (n = 750 individuals) (C). Lines represent the receiver operating characteristic area under the curve point estimate (middle point) and 95% confidence intervals. Black lines represent correspondence in the entire cohort and the red lines represent correspondence in amyloid PET positive individuals.
Extended Data Fig. 1 Correspondence of CSF measures with amyloid PET status, tau PET status, or clinical status. Correspondence of the CSF measures with amyloid PET status was evaluated in the amyloid PET cohort (n = 750 individuals) (A), and correspondence with tau PET status was evaluated in tau PET cohort (n = 371 individuals) (B). Correspondence of the CSF measures with clinical status (cognitively normal [CDR = 0] or cognitively impaired [CDR > 0]) was evaluated in the larger amyloid PET cohort (n = 750 individuals) (C). Lines represent the receiver operating characteristic area under the curve point estimate (middle point) and 95% confidence intervals. Black lines represent correspondence in the entire cohort and the red lines represent correspondence in amyloid PET positive individuals.CC BY · PubMed Central
Extended Data Fig. 2 Receiver operating characteristic curves for selected CSF measures. Correspondence of selected CSF measures with amyloid PET status was evaluated in the amyloid PET cohort; n = 750 for all measures shown (A). Correspondence of selected CSF measures with tau PET status was evaluated in the tau PET cohort; n = 371 for all measures shown except for pT181/T181 and p-tau181 (n = 370) (B). Correspondence of selected CSF measures with tau PET status was evaluated in the amyloid PET positive individuals in the tau PET cohort; n = 125 for all measures shown (C). For each measure, the receiver operating characteristic area under the curve with 95% confidence intervals is shown.
Extended Data Fig. 2 Receiver operating characteristic curves for selected CSF measures. Correspondence of selected CSF measures with amyloid PET status was evaluated in the amyloid PET cohort; n = 750 for all measures shown (A). Correspondence of selected CSF measures with tau PET status was evaluated in the tau PET cohort; n = 371 for all measures shown except for pT181/T181 and p-tau181 (n = 370) (B). Correspondence of selected CSF measures with tau PET status was evaluated in the amyloid PET positive individuals in the tau PET cohort; n = 125 for all measures shown (C). For each measure, the receiver operating characteristic area under the curve with 95% confidence intervals is shown.CC BY · PubMed Central
Extended Data Fig. 3 Correlations of selected CSF p-tau concentrations and tau phosphorylation occupancies with amyloid PET Centiloid in the BioFINDER-2 cohort. CSF concentrations of p-tau217 (A), p-tau231 (C), p-tau181 by MS (E), p-tau205 (G), and Aβ42 (I) and tau phosphorylation occupancies at T217 (B), T231 (D), T181 (F), T205 (H), as well as Aβ42/Aβ40 (J), are plotted as a function of amyloid PET Centiloid. Spearman correlations with 95% confidence intervals are shown. Vertical dashed lines represent the cut-off for amyloid PET positivity. Each symbol represents one individual: green square: amyloid PET negative, CSF positive, CDR > 0; red circle: amyloid PET positive, CSF positive, CDR = 0.5; red square: amyloid PET positive, CSF positive, CDR > 0.5.
Extended Data Fig. 3 Correlations of selected CSF p-tau concentrations and tau phosphorylation occupancies with amyloid PET Centiloid in the BioFINDER-2 cohort. CSF concentrations of p-tau217 (A), p-tau231 (C), p-tau181 by MS (E), p-tau205 (G), and Aβ42 (I) and tau phosphorylation occupancies at T217 (B), T231 (D), T181 (F), T205 (H), as well as Aβ42/Aβ40 (J), are plotted as a function of amyloid PET Centiloid. Spearman correlations with 95% confidence intervals are shown. Vertical dashed lines represent the cut-off for amyloid PET positivity. Each symbol represents one individual: green square: amyloid PET negative, CSF positive, CDR > 0; red circle: amyloid PET positive, CSF positive, CDR = 0.5; red square: amyloid PET positive, CSF positive, CDR > 0.5.CC BY · PubMed Central
Extended Data Fig. 4 Correlations of selected CSF p-tau concentrations and tau phosphorylation occupancies with tau PET SUVR for Braak I-IV regions in the BioFINDER-2 cohort. CSF concentrations of p-tau205 (A), p-tau217 (C), p-tau208 (E), p-tau231 (G), and p-tau181 by MS (I) and tau phosphorylation occupancies at T205 (B), T217 (D), S208 (F), T231 (H), as well as T181 (J), are plotted as a function of the tau PET SUVR for Braak I-IV regions. Spearman correlations with 95% confidence intervals are shown. Vertical dashed lines represent the cut-off for tau PET positivity (SUVR > 1.32 for Braak I-IV regions). Each symbol represents one individual: green square: amyloid PET negative, CSF positive, CDR > 0; red circle: amyloid PET positive, CSF positive, CDR = 0.5; red square: amyloid PET positive, CSF positive, CDR > 0.5.
Extended Data Fig. 4 Correlations of selected CSF p-tau concentrations and tau phosphorylation occupancies with tau PET SUVR for Braak I-IV regions in the BioFINDER-2 cohort. CSF concentrations of p-tau205 (A), p-tau217 (C), p-tau208 (E), p-tau231 (G), and p-tau181 by MS (I) and tau phosphorylation occupancies at T205 (B), T217 (D), S208 (F), T231 (H), as well as T181 (J), are plotted as a function of the tau PET SUVR for Braak I-IV regions. Spearman correlations with 95% confidence intervals are shown. Vertical dashed lines represent the cut-off for tau PET positivity (SUVR > 1.32 for Braak I-IV regions). Each symbol represents one individual: green square: amyloid PET negative, CSF positive, CDR > 0; red circle: amyloid PET positive, CSF positive, CDR = 0.5; red square: amyloid PET positive, CSF positive, CDR > 0.5.CC BY · PubMed Central
Extended Data Fig. 5 Correlations of selected CSF p-tau concentrations and tau phosphorylation occupancies with tau PET SUVR for Braak V-VI regions in the BioFINDER-2 cohort. CSF concentrations of p-tau205 (A), p-tau217 (C), p-tau208 (E), p-tau231 (G), and p-tau181 by MS (I) and tau phosphorylation occupancies at T205 (B), T217 (D), S208 (F), T231 (H), as well as T181 (J), are plotted as a function of the tau PET SUVR for Braak V-VI regions. Spearman correlations with 95% confidence intervals are shown. Each symbol represents one individual: green square: amyloid PET negative, CSF positive, CDR > 0; red circle: amyloid PET positive, CSF positive, CDR = 0.5; red square: amyloid PET positive, CSF positive, CDR > 0.5.
Extended Data Fig. 5 Correlations of selected CSF p-tau concentrations and tau phosphorylation occupancies with tau PET SUVR for Braak V-VI regions in the BioFINDER-2 cohort. CSF concentrations of p-tau205 (A), p-tau217 (C), p-tau208 (E), p-tau231 (G), and p-tau181 by MS (I) and tau phosphorylation occupancies at T205 (B), T217 (D), S208 (F), T231 (H), as well as T181 (J), are plotted as a function of the tau PET SUVR for Braak V-VI regions. Spearman correlations with 95% confidence intervals are shown. Each symbol represents one individual: green square: amyloid PET negative, CSF positive, CDR > 0; red circle: amyloid PET positive, CSF positive, CDR = 0.5; red square: amyloid PET positive, CSF positive, CDR > 0.5.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 154

Metadata

Authors
Barthélemy, N. R., Saef, B., Li, Y., Gordon, B. A., He, Y., Horie, K., Stomrud, E., Salvadó, G., Janelidze, S., Sato, C., Ovod, V., Henson, R. L., Fagan, A. M., Benzinger, T. L. S., Xiong, C., Morris, J. C., Hansson, O., Bateman, R. J., & Schindler, S. E.
Affiliations
  • Washington University in St. Louis (US)
  • Lund University (SE)
Corresponding author
  • Barthélemy, Nicolas R.
  • Schindler, Suzanne E.
Venue
Nature Aging
Published
2023-03-13
Volume
3
Issue
4
Pages
391-401
ISSN
2662-8465 (ISSN-L)
OpenAlex
W4324032790
Cited by
153
References
51
Citations by year
2026: 29 · 2025: 56 · 2024: 58 · 2023: 10
FWCI
27.17
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Aging (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Knight ADRC Developmental Award
  • Eisai industry award
  • U.S. Department of Health & Human Services | NIH | National Institute on Aging (P30AG066444, P01AG003991, P01AG026276, U19AG032438, U19AG024904, RF1AG061900, R56AG061900, R01AG070941)
  • Vetenskapsrådet (2016-00906)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords
Alzheimer's disease, cerebrospinal fluid biomarkers, tau phosphorylation, amyloid PET, amyloid-beta 42/40 ratio, tau PET, tau pathology
MeSH terms
Aged, Alzheimer Disease, Amyloid, Humans, Peptide Fragments, Phosphorylation, Biomarkers, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease. https://app.cochat.ai/papers/10.1038/s43587-023-00380-7
The paper
Barthélemy, N. R., Saef, B., Li, Y., Gordon, B. A., He, Y., Horie, K., Stomrud, E., Salvadó, G., Janelidze, S., Sato, C., Ovod, V., Henson, R. L., Fagan, A. M., Benzinger, T. L. S., Xiong, C., Morris, J. C., Hansson, O., Bateman, R. J., & Schindler, S. E. (2023). CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease. Nature Aging. https://doi.org/10.1038/s43587-023-00380-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.